微创直视冠状动脉旁路移植术的极长期结局
该回顾性研究评估了141例1997—2017年接受MIDCAB患者的20年安全性、总生存率及免于MACCE情况,并与133例全胸骨正中切开行左乳内动脉至左前降支血运重建患者比较。结果显示MIDCAB极长期生存与免于MACCE令人满意,且住院时间更短、输血及心脏相关事件和全因事件更少。
要点
- MIDCAB术后20年生存率70%,免于MACCE率61%。
- 年龄、癌症、慢性肾功能不全是长期生存的独立预测因素。
- 与全胸骨切开相比,MIDCAB住院更短、输血及事件更少。
核心结论
- MIDCAB极长期生存和免于MACCE的临床结局令人满意。
- 与全胸骨正中切开行左前降支血运重建相比,MIDCAB显著缩短住院时间并减少输血,且在心脏相关事件和全因事件方面似乎有效改善预后。
研究设计与样本
- 回顾性收集1997—2017年接受MIDCAB的141例患者评估长期结局。
- 另分析133例经全胸骨正中切开行左乳内动脉至左前降支血运重建的患者作为对照。
主要发现
- Kaplan-Meier曲线示1、5、10、15、20年生存率分别为100%、95%、90%、83%、70%。
- 免于MACCE(心肌梗死、卒中、心源性死亡)在1、5、10、15、20年分别为97%、90%、79%、75%、61%。
- Cox多因素分析示年龄、癌症、慢性肾功能不全是影响长期生存的独立预测因素,风险比分别为1.12(P = .007)、17.63(P < .001)、5.16(P = .03)。
- MIDCAB组住院时间显著更短,输血率、心脏相关事件率及全因事件率显著更低(P = .02和P = .001)。
临床怎么用
- 对于适合的左前降支病变患者,MIDCAB可作为全胸骨切开冠脉旁路移植的替代术式,以缩短住院和减少输血。
- 术后长期随访应关注年龄、癌症及慢性肾功能不全等高危因素对生存的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive direct coronary artery bypass (MIDCAB) is a well-established, low-impact surgical procedure for revascularization of the left descending coronary artery with the left internal mammary artery. This study aimed to evaluate safety, overall survival, and freedom from major adverse cardiocerebral-related events (MACCE) after 20 years of MIDCAB. METHODS: This study retrospectively collected a series of 141 patients who underwent MIDCAB between 1997 and 2017, to assess long-term outcome. A total of 133 patients who underwent revascularization of the left descending coronary artery with the left mammary artery through a full median sternotomy were analyzed. RESULTS: Actuarial survival rates on a Kaplan-Meier curve were 100%, 95%, 90%, 83%, and 70% at 1, 5, 10, 15, and 20 years, respectively. Freedom from MACCE, defined as myocardial infarction, stroke, and cardiac death, was 97%, 90%, 79%, 75%, and 61% at 1,5,10,15, and 20 years, respectively. At Cox multivariable analysis, age, cancer, and chronic renal insufficiency were found to be independent predictors affecting long-term survival, with a hazard ratio of 1.12 (P = .007), 17.63 (P < .001), and 5.16 (P = .03), respectively. The MIDCAB group showed a significantly shorter hospital length of stay and significantly lower rates of blood transfusions, cardiac-related events, and all-cause events compared with the full sternotomy group (P = .02 and P = .001, respectively). CONCLUSIONS: The very long-term clinical outcome of MIDCAB is satisfactory in terms of survival and freedom from MACCE. MIDCAB significantly reduces hospital length of stay and blood transfusions when compared with full sternotomy bypass surgery on the left descending coronary artery and appears to improve prognosis in terms of cardiac-related events and all-cause events effectively.
引用
- Mastroiacovo G, Manganiello S, Pirola S, et al. Very Long-term Outcome of Minimally Invasive Direct Coronary Artery Bypass. Ann Thorac Surg. 2020. PMID: 32818539. doi:10.1016/j.athoracsur.2020.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。